Wilsons Equity Research Report Issued with Buy Rating
Zoetis is already calling out a negative impact on their medicated feed additive sales just three months into the Veterinary Feed Directive rules coming into force, which switched key swine and cattle products from over-the-counter to prescription only. Zoetis has led the industry on the "antibiotic stewardship" issue and we think it has genuine intentions towards making Detach available to producers.
Wilsons Equity Research
Issued by Wilsons Advisory and Stockbroking Limited ABN 68 010 529 665 - Australian Financial Services Licence No 238375, a participant of ASX Group and should be read in conjunction with the disclosures and disclaimer in this report. Important disclosures regarding companies that are subject of this report and an explanation of recommendations can be found at the end of this document.
To view the Research Report, please visit:
About Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) develops and aims to partner non-antibiotic, oral products for gastrointestinal diseases in animals and humans where there is significant unmet need and large market opportunity. In May 2018, Anatara granted an exclusive licence to the leading global animal health company, Zoetis Inc., for the worldwide development, manufacturing, distribution and marketing of its lead product Detach as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses. Anatara is now focused on developing its human product pipeline for gastrointestinal health applications. For more information, please visit www.anataralifesciences.com.
Anatara Lifesciences Ltd